Ana Ruiz-Saenz
Overview
Explore the profile of Ana Ruiz-Saenz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
324
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Vincken R, Ruiz-Saenz A
STAR Protoc
. 2023 Apr;
4(2):102224.
PMID: 37071532
Current protocols measure antibody-dependent cellular cytotoxicity (ADCC) in vitro using peripheral blood mononuclear cells (PBMCs), but isolation and variability among donors limit the viability and reproducibility of this approach. Here,...
2.
Ruiz-Saenz A, Atreya C, Wang C, Pan B, Dreyer C, Brunen D, et al.
Nat Cancer
. 2023 Feb;
4(2):240-256.
PMID: 36759733
BRAF mutation confers a poor prognosis in metastatic colorectal cancer (CRC) despite combinatorial targeted therapies based on the latest understanding of signaling circuitry. To identify parallel resistance mechanisms induced by...
3.
Campbell M, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, et al.
Cell Rep
. 2022 Sep;
40(10):111338.
PMID: 36070686
No abstract available.
4.
Campbell M, Ruiz-Saenz A, Zhang Y, Peterson E, Steri V, Oeffinger J, et al.
Cell Rep
. 2022 Feb;
38(5):110285.
PMID: 35108526
Surface-targeting biotherapeutic agents have been successful in treating HER2-amplified cancers through immunostimulation or chemodelivery but have failed to produce effective inhibitors of constitutive HER2-HER3 signaling. We report an extensive structure-function...
5.
Campbell M, Ruiz-Saenz A, Peterson E, Agnew C, Ayaz P, Garfinkle S, et al.
Cell Rep
. 2022 Feb;
38(5):110291.
PMID: 35108525
Effective inactivation of the HER2-HER3 tumor driver has remained elusive because of the challenging attributes of the pseudokinase HER3. We report a structure-function study of constitutive HER2-HER3 signaling to identify...
6.
Ruiz-Saenz A, Zahedi F, Peterson E, Yoo A, Dreyer C, Spassov D, et al.
Mol Cancer Res
. 2021 Mar;
19(6):957-967.
PMID: 33727342
The Src family kinases (SFK) are homologs of retroviral oncogenes, earning them the label of proto-oncogenes. Their functions are influenced by positive and negative regulatory tyrosine phosphorylation events and inhibitory...
7.
Kazemi S, Kawaguchi S, Badr C, Mattos D, Ruiz-Saenz A, Serrill J, et al.
Biochem Pharmacol
. 2020 Nov;
183:114317.
PMID: 33152346
Coibamide A is a potent cancer cell toxin and one of a select group of natural products that inhibit protein entry into the secretory pathway via a direct inhibition of...
8.
Coppe J, Mori M, Pan B, Yau C, Wolf D, Ruiz-Saenz A, et al.
Nat Cell Biol
. 2019 Jun;
21(6):778-790.
PMID: 31160710
Phosphorylation networks intimately regulate mechanisms of response to therapies. Mapping the phospho-catalytic profile of kinases in cells or tissues remains a challenge. Here, we introduce a practical high-throughput system to...
9.
Spassov D, Ruiz-Saenz A, Piple A, Moasser M
Cell Rep
. 2018 Oct;
25(2):449-463.e4.
PMID: 30304684
The mode of regulation of Src kinases has been elucidated by crystallographic studies identifying conserved structured protein modules involved in an orderly set of intramolecular associations and ligand interactions. Despite...
10.
Ruiz-Saenz A, Dreyer C, Campbell M, Steri V, Gulizia N, Moasser M
Cancer Res
. 2018 May;
78(13):3645-3658.
PMID: 29760043
Current evidence suggests that HER2-driven tumorigenesis requires HER3. This is likely due to the unique ability of HER3 to activate PI3K/Akt pathway signaling, which is not directly accessible to HER2....